Pfizer on track for U.S. vaccine boosters, Moderna lagging, Fauci says
06 Sep 2021
Pfizer (NYSE:PFE) is trading flat at 46.84
Top U.S. infectious disease expert Rd. Anthony Fauci said on Sunday that officials were likely to soon get the regulatory go-ahead to administer COVID-19 vaccine booster shots made by Pfizer (NYSE:PFE), although Moderna (NASDAQ:MRNA) booster could take a little longer.
Asked on CBS’ “Face the Nation,” about President Joe Biden’s goal to give booster shots starting Sept. 20, Fauci said that “in some respects” that remained the plan.
But he said that while Pfizer-BioNTech has submitted the necessary data on booster shots to the Food and Drug Administration (FDA), Moderna has yet to complete the process. Fauci said he hopes to give both vaccines when boosters doses roll out, but if Moderna does not complete the process before Sept. 20, then Moderna boosters will be given later.
Moderna and the FDA did not immediately return emails seeking comment. In a statement released Wednesday, Moderna said it had “initiated its submission” of booster data to the FDA.
How – or even whether – to administer boosters has emerged as a thorny issue as COVID-19 continues to kill unvaccinated people around the world.
On technical fronts Pfizer (NYSE:PFE) RSI stood at 53.36 and currently stock is trading above all Moving Average. So, BUY position can be taken with following target and stoploss:
TRADE SIGNAL – : Pfizer (NYSE:PFE) – BUY: 46.84, TARGET: 48.16, STOP LOSS : 45.94